This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nieroda, C. A. Articles by Greiner, J. W. Search for Related Content PubMed PubMed Citation Articles by Nieroda, C. A. Articles by Greiner, J. W.

Improved Tumor Radioimmunodetection Using a Single-Chain Fv and -Interferon: Potential Clinical Applications for Radioimmunoguided Surgery and Scanning

Laboratory of Tumor Immunology and Biology [C. A. N., D. E. M., J. S., J. W. G.] and Department of Nuclear Medicine [J. A. C.], National Cancer Institute, NIH, Bethesda, Maryland 20892

Previous studies have shown that (a) single-chain antibody binding proteins, or sFvs, localize experimental tumor xenografts (D. E. Milenic et al., Cancer Res., 51: 6363–6371, 1991) and (b) the administration of -interferon (IFN-) increases the expression of a high molecular weight glycoprotein, tumor-associated glycoprotein 72 (TAG-72), which improves mAb-based tumor targeting as well as radioimmunotherapy (J. W. Greiner et al., Cancer Res., 53: 600–608, 1993). The present experimental study was designed to determine whether exploiting those two observations in combination could augment tumor detection. Initial results revealed significant localization of a single-chain antibody binding protein of CC49 (i.e., CC49 sFv), a second generation anti-TAG-72 mAb, to human colon tumor xenografts (HT-29), which express low constitutive TAG-72 levels. IFN- treatment of mice bearing HT-29 tumors significantly increased TAG-72 levels in the tumor xenografts. Increased TAG-72 expression was accompanied by a 2–4-fold augmentation of CC49 sFv localized to the HT-29 tumors, measured by direct quantitation of ¹²⁵I-labeled CC49 sFv tumor deposition as well as tumor:normal tissue ratios. Enhanced CC49 sFv tumor localization improved HT-29 tumor visualization by external scintigraphy as well as when using a hand-held gamma-detecting probe to discriminate between normal (i.e., heart, hind leg) and tumor tissue. The gamma-detecting probe was the same as that used intraoperatively with ¹²⁵I-labeled CC49 IgG to identify occult tumors in patients. The present experimental findings indicate that the efficiency by which ¹²⁵I-labeled CC49 sFv localizes tumor in vivo can be enhanced with IFN-. Results of the present study suggest that (a) the incorporation of an IFN- treatment schema prior to radioimmunoscintigraphy may increase the signal from the tumor site(s), thus providing a better discrimination between tumor and background, and (b) combining ¹²⁵I-labeled CC49 sFv with IFN- will not only reduce the time interval between antibody injection and surgery, but will also increase the efficiency of tumor localization using the intraoperative gamma-detecting probe.

¹ To whom requests for reprints should be addressed, at Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Building 10, Room 8B07, Bethesda, MD 20892.

Received 2/ 3/95. Accepted 5/ 3/95.

This article has been cited by other articles:

				A. Goel, J. Baranowska-Kortylewicz, S. H. Hinrichs, J. Wisecarver, G. Pavlinkova, S. Augustine, D. Colcher, B. J.M. Booth, and S. K. Batra 99mTc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma J. Nucl. Med., October 1, 2001; 42(10): 1519 - 1527. [Abstract] [Full Text] [PDF]

				C.-T. Kuan, C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts Clin. Cancer Res., June 1, 1999; 5(6): 1539 - 1549. [Abstract] [Full Text] [PDF]

				J.-M. Kupsch, N. H. Tidman, N. V. Kang, H. Truman, S. Hamilton, N. Patel, J. A. Newton Bishop, I. M. Leigh, and J. S. Crowe Isolation of Human Tumor-specific Antibodies by Selection of an Antibody Phage Library on Melanoma Cells Clin. Cancer Res., April 1, 1999; 5(4): 925 - 931. [Abstract] [Full Text] [PDF]